Redeye provides a research update following the Q3 report published by OncoZenge earlier today.
The announced acquisition of Kapsch TrafficCom’s North American components business (KNAMC) appears ...
Redeye provides a research update following AlzeCure's Q3 report.
The US FDA has commenced an inspection of Xspray Pharma’s contract manufacturer NerPharMa, marking a...
Kraftig försäljningstillväxt med stöd av tillfälliga effekter Nettoomsättningen ökade med 82,0 % ti...
*€135m equity financing ambition, with substantial incentives for long-term investors.
Flughafen Wien will report Q3 results on 19 November.
We downgrade Steyr Motors from BUY to HOLD and set a technical PT of € 39 (prev.
On 19 November, NFON will publish its Q3 report. We expect another decline on the top line, while pr...
At yesterday's Capital Markets Day, Modelon presented three new AI-based offerings – Modelon Credits...
Redeye provides an initial take following the release of BICO's Q3 2026 report.
TagMaster intends to acquire Kapsch TrafficCom’s RFID-focused North American components business (KN...
InfraCom's Q3 report showed net sales of SEK204.6m, 5% above our SEK194m and up 4% y/y, with Communi...
Redeye comments on Embracer’s Q2-results which were stronger-than-expected, with both Fellowship and...
* Sales SEK 1,216m & EBIT 69m * Earnings beat driven by US * Share currently trading at 11-9x '26e-'...
Genovis' Q3 release was a beat across the board showing growth, operating leverage and solid cash fl...
Redeye comments on Isofol’s new update from the ongoing phase Ib/II study with arfolitixorin.
* CMD likely to highlight market position and structural demand drivers * Business unit deep dive an...
* We raise '27e/'28e EBIT by 7%/5%, driven by cost savings * Positioned to increase EBIT and FCF in ...
Hyresintäkter steg 15% till 633 mkr och förvaltningsresultatet 11% till 212 mkr (justerat för engång...